TNBC has the greatest immunogenicity, and therefore clinical studies of anti-PD-1/PD-L1 were conducted for this type of tumor, the response to which was determined in 18.5 [9]—20% of patients [10]. The gene discussed is CD274; the disease is neoplasm.